

Iceland, Ireland, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and The United Kingdom.

**ADDRESSES:** Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

**FOR FURTHER INFORMATION CONTACT:** Cathy E. Conn, Center for Biologics Evaluation and Research (HFM-610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-594-2006.

**SUPPLEMENTARY INFORMATION:** The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of human biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Ortho Diagnostic Systems, Inc., 1001 U.S. Hwy. 202, Raritan, NJ 08869-0606, has filed an application requesting approval for the export of the

human biological product SELECTOGEN® 0.8%, Reagent Red Blood Cells to Australia, Austria, Belgium, Canada, Denmark, The Federal Republic of Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, and The United Kingdom. The SELECTOGEN® 0.8%, Reagent Red Blood Cells, is an in vitro diagnostic test kit for the detection of unexpected blood group antibodies in test methods requiring a 0.8 percent red cell suspension in a low ionic strength diluent. The application was received and filed in the Center for Biologics Evaluation and Research on November 24, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by January 2, 1996, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Biologics Evaluation and Research (21 CFR 5.44).

Dated: December 4, 1995.

James C. Simmons,

*Director, Office of Compliance, Center for Biologics Evaluation and Research.*

[FR Doc. 95-30886 Filed 12-19-95; 8:45 am]

BILLING CODE 4160-01-F

## Health Resources and Services Administration

### Agency Forms Undergoing Paperwork Reduction Act Review

Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget, in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for review, call the HRSA Reports Clearance Office on (301) 443-1129.

The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995:

National Practitioner Data Bank for Adverse Information on Physicians and Other Health Care Practitioners: Regulations and Forms (OMB No. 0915-0126)—Extension, No Change—The Data Bank forms and regulations received a short-term approval in June 1995. As part of the terms of clearance, HRSA was required to submit an updated analysis of small medical malpractice payments (concerning the issue of monetary threshold reporting of claims) and provide OMB with an updated chart of the distribution of malpractice awards. The requirements have been satisfied and the Data Bank regulations and forms are now being resubmitted for a 3-year approval. This request is for an extension with no changes. The burden estimates are as follows:

Title	Number of respondents	Frequency of response	Number of responses	Hours per response	Total burden hours
60.6(a) Reporting Corrections of Errors and Omissions .....	2,800	1.04	2,925	.25	731
60.6(b) Revisions to Original Report Actions .....	350	1.06	370	.75	278
60.7(b) Reporting Medical Malpractice Payments .....	150	105.33	15,800	.75	11,850
60.8(b) Reporting Licensure Action by State Boards .....	125	21.02	2,630	.75	1,973
60.9(a) Reporting Privileging and Professional Society Actions .....	1,000	1.08	1,075	.75	806
60.9(c) Request for Hearings by Entities Found in Noncompliance .....	1	1	1	8.00	8
60.10(a)(1) Hospital Queries on Applicants; 60.11(a)(1) Other Hospital Queries; 60.11(a)(6) Queries for Professional Review .....	7,200	38.33	276,000	.08	23,000
60.10(a)(2) Biennial Queries by Hospitals .....	6,000	186.83	1,121,000	.08	93,417
60.11(a)(2) Practitioner Queries .....	29,000	1	29,000	.25	7,250
60.11(a)(3) State Licensure Board Queries .....	70	171	12,000	.08	1,000
60.11(a)(4) Queries by Non-hospital Health Care Entities .....	1,860	139.78	260,000	.08	21,667
60.11(a)(5) Queries by Attorneys .....	10	1	10	.25	3
60.11(a)(7) Queries for Research Purposes .....	100	1	100	1.00	100
60.14(b) Practitioner's Disputing Data Bank Reports .....	1,080	1	1,080	.17	180
60.14(b) Practitioner Requests for Secretarial Review .....	100	1	100	8.00	800
60.14(b) Practitioner Statements .....	2,700	1	2,700	1.00	2,700

Title	Number of respondents	Frequency of response	Number of responses	Hours per response	Total burden hours
Biennial Entity Verification Document .....	5,750	1	5,750	.25	1,438
Entity File Update .....	1,150	1	1,150	.25	288

Estimated Total Annual Burden:  
167,489 hours

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Allison Eydt, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: December 14, 1995.

J. Henry Montes,

Associate Administrator for Policy  
Coordination

[FR Doc. 95-30885 Filed 12-19-95; 8:45 am]

BILLING CODE 4160-15-U

**National Institutes of Health**

**Opportunity For Licensing: Sequence Modification of Oligonucleotide Primers to Manipulate Non-Templated Nucleotide Addition**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** The National Institutes of Health (NIH) seeks licensees to commercialize a method to manipulate non-templated nucleotide addition to ensure that all amplified DNA products of polymerase chain reaction (PCR) are either specifically modified or unmodified.

This technology was developed by Dr. Jeffrey R. Smith and Dr. John Carpten of the National Center for Human Genome Research and Dr. Michael Brownstein of the National Institute of Mental Health.

The invention embodied in U.S. Provisional Patent Application 60/005, 761 filed October 20, 1995, entitled "Sequence Modification of Oligonucleotide Primers to Manipulate Non-Templated Nucleotide Addition," is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 or pursuant to 42 U.S.C. 241 to achieve expeditious commercialization of results of federally-funded research and development.

**ADDRESSES:** Requests for a summary of the technology or other questions and comments concerning the biomedical aspects of this technology should be directed to: Dr. Ronald King, National

Center for Human Genome Research, 9000 Rockville Pike, Building 31, Room 3B13, Bethesda, MD 20892; Telephone: 301/402-2537; Fax 301/402-9722.

Requests for a copy of the patent application, license application form, or other questions and comments concerning the licensing of this technology should be directed to: Carol Lavrich, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone 301/496-7735 ext 287; Fax 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

**SUPPLEMENTARY INFORMATION:**

Thermostable DNA polymerases are employed in PCR to amplify DNA for sizing in medical diagnostics, forensics, and genotyping, as well as for molecular cloning. Several of these enzymes, including the widely used Taq DNA polymerase, can catalyze non-templated addition of a nucleotide (predominantly adenosine) to the 3' end of amplification products. As a result, an amplified DNA fragment may be incorrectly sized by one base pair in length and introduce error into a genotyping study. Artifactual variations in marker size may adversely impact interpretations of family relationships, medical diagnosis, and forensics. Moreover, full automation of genotyping has been hampered by the necessity of manually editing collected data to correct for allele misidentification due to the unpredictability of non-templated nucleotide addition. In addition, TA cloning methods that rely upon the modification will often fail when the amplified DNA is not modified.

In response to this problem, Drs. Smith, Carpten, and Brownstein have characterized short DNA sequences ("tails") that may be added to the unlabeled primer of a PCR primer pair to confer modification by a thermostable DNA polymerase, or to protect from the modification. This allows uniformity in allele sizing that is essential for automated genotyping. Furthermore, this prevents introduction of error and enables high TA cloning efficiency.

The NIH seeks licensee(s), who in accordance with requirements and regulations governing the licensing of government-owned inventions (37 CFR part 404), have the most meritorious

plan for the development of this method to meet the needs of the public and with the best terms for the NIH. The criteria that NIH will use to evaluate exclusive or non-exclusive license applications will include those set forth by 37 CFR 404.7(a)(1)(ii)-(iv).

Dated: December 8, 1995.

Barbara M. McGarey,  
Deputy Director, Office of Technology  
Transfer.

[FR Doc. 95-30935 Filed 12-19-95; 8:45 am]

BILLING CODE 4140-01-M

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

**ADDRESSES:** Licensing information and a copy of the U.S. patent application referenced below may be obtained by contacting Robert Benson at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7056 ext 267; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

**Immunogenic Chimeras Comprising Nucleic Acid Sequences Encoding Endoplasmic Reticulum Signal Sequence Peptides and at Least One Other Peptide, and Their Uses in Vaccines and Disease Treatments**

Nicholas P. Restifo, Steven A. Rosenberg, Jack R. Bennink, Igor Bacik, and Jonathan W. Yewdell (NCI)  
Serial Number 08/032,902 filed March 17, 1993

This invention concerns the use of chimeric peptides as vaccines for the cellular immune system. One portion of the chimeric peptide, the ER signal peptide, serves to transport the chimeric